The Study Of Budesonide/Formoterol In The Treatment Of Severe Chronic Obstructive Pulmonary Disease

Background：Chronic obstructive pulmonary disease is a kind of airflowlimitation is not fully reversible, and the progressive development of the can intreatment and prevention of disease, its incidence and cigarette smoke and otherharmful gas and the harmful inflammatory response, COPD can cause systemicadverse reactions, but primarily affects the lung. World Bank/World HealthOrganization is expected to COPD in2020, will be among the world’s diseaseburden5. COPD is a worldwide disease, disability and cause of death graduallyincreased to the socio-economic burden, and seriously affect the quality of lifeof patients.A lot of evidence to suggest that short-acting cholinergic antagonists canimprove the symptoms of patients with COPD, lung function and improvequality of life. Theophylline as an antispasmodic, antiasthmatic drugs wasrecognized in recent years also found that small doses of theophylline canenhance the anti-inflammatory effects of the hormone. The GOLD guidelinesrecommend long-term inhaled corticosteroids and long-acting β2-agonist, canimprove lung function, improve quality of life, reduce the frequency of acuteexacerbations of severe COPD patients. The safety and tolerability of the threedrugs has been fully affirmed. In our country ipratropium bromide andtheophylline as an antispasmodic, antiasthmatic drugs are widely used inclinical treatment of COPD. Budesonide/formoterol is mainly used in severeCOPD, especially patients with a history of frequent heavier. Bronchialrelaxation and anti-inflammatory mechanisms of the three drugs, it hasfrequently aggravated in patients with a history of moderate to severe COPDand the conjunction of the three drugs is bound to get more satisfactory results. Purpose：The main purpose of this test is to evaluate the long-termstability of patients with severe COPD, regular, joint inhaled budesonide/formoterol efficacy and safety.Methods：This study was randomized, parallel, open, controlled clinicalstudy.COPD patients eligible to enter a period of two weeks in period,Patientsmust use ipratropium20ug/suction, two suction4times a day+Sustainedrelease theophylline0.1g/tablet,1tablets orally2times daily as a maintenancetreatment.14days after the import of patients met inclusion criteria duringfollow-up were randomly assigned as experimental group and control groupinto the12-week treatment period, the experimental group increase in theipratropium bromide, theophylline treatment on the basis of the letter will Paul160/4.5ug/suction, two suction2times a day, control group treatment programunchanged. Throughout the study period will be provided to patients withshort-acting β2agonist-salbutamol aerosol (Ventolin, Glaxo Smith Kline) asrescue medication. Patient revisit3,4,6,8ECG, blood pressure, heart rate,physical examination checks will be conducted to fill in the SGRQ linepulmonary function test.Results：The test group for12weeks after pulmonary function indiceswere reduced, and the visit of3there is no significant difference (P>0.05), butimprove the quality of life score is reduced, and the visit of3had a significantdifference (P <0.05).The test group for12weeks after lung function, quality oflife score a visit to3and control group had significant improvement, thedifference was statistically significant (P <0.05).Test group and control group,blood pressure, heart rate, ECG examination showed no abnormalities, only2cases of test group patients with hoarseness, suggest to the water aftersymptoms disappear, two groups of adverse events with no statisticallysignificant difference (P>0.05).